GTPases and phospholipase C isozymes are validated therapeutic targets and KXTbio has created and patented unique reagents and assays that enable high-throughput screens for these classes of proteins. Our screens allow us to rapidly identify lead hits that modulate these proteins and that can be used to launch drug discovery programs.
Please contact us if you believe KXTbio can facilitate your discovery and development process and you wish to explore a partnership with us.
